Clinical Trials Logo

Adenocarcinoma of the Pancreas clinical trials

View clinical trials related to Adenocarcinoma of the Pancreas.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03778879 Withdrawn - Pancreas Cancer Clinical Trials

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

Start date: August 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy. However, the pancreatic cancer often comes back after this treatment. Therefore, the investigators are studying whether giving treatment prior to surgery can help decrease the risk the cancer returns. Stereotactic Body Radiation Therapy (SBRT) is a highly focused type of radiation therapy commonly used in the treatment of pancreatic cancer. This treatment has been shown to be safe and effective for the preoperative treatment of pancreatic cancer. The purpose of this study is to determine if combining an experimental drug, CCX872-B, with SBRT continues to be safe and whether the combination treatment may be more effective at boosting the participant's immune system's ability to kill the pancreatic cancer.

NCT ID: NCT03065985 Withdrawn - Clinical trials for Adenocarcinoma of the Pancreas

EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma.

Start date: August 2017
Phase: Phase 2
Study type: Interventional

This study will assess if endoscopic ultrasound radiofrequency application in patients with inoperable pancreatic cancer and chemotherapy confers survival benefit when compared to patients receiving best medical care and chemotherapy .

NCT ID: NCT01401387 Withdrawn - Clinical trials for Adenocarcinoma of the Pancreas

Pancreatic Enzyme Suppletion in Pancreatic Cancer

EPC
Start date: October 2011
Phase: Phase 4
Study type: Interventional

This study will evaluate the effect of immediate pancreatic enzyme suppletion on the physical and mental health status and survival of patients who are diagnosed with pancreatic cancer and are highly likely to develop exocrine pancreatic insufficiency during their disease process.

NCT ID: NCT00253526 Withdrawn - Clinical trials for Stage III Pancreatic Cancer

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how well they work compared to gemcitabine hydrochloride alone in treating patients who are undergoing surgery for pancreatic cancer.